Literature DB >> 24497889

Myocardial infarction type 4b in human immunodeficiency virus-infected patient.

Aneta Cybula-Walczak1, Filip M Szymanski2, Anna E Platek2, Grzegorz Karpinski2.   

Abstract

We report a case of a 52-year-old human immunodeficiency virus (HIV)-infected male patient receiving combined antiretroviral therapy (cART), who presented with acute ST-elevation myocardial infarction (STEMI). He was properly treated (e.g., prescribed anti-coagulation drugs: aspirin, clopidogrel, enoxaparin) and discharged. After 1.5 months, another STEMI related with in-stent thrombosis took place. The cART scheme was altered, resulting in no further cardiac events in the follow-up period, with undetectable levels of HIV ribonucleic acid. This case highlights the association between HIV infection and the specific drugs of cART, and the risk of cardiovascular disease development.

Entities:  

Keywords:  Antiretroviral therapy; Human immunodeficiency virus; Myocardial infarction

Year:  2014        PMID： 24497889      PMCID： PMC3905115          DOI： 10.4070/kcj.2014.44.1.42

Source DB:  PubMed          Journal:  Korean Circ J        ISSN： 1738-5520            Impact factor:   3.243


  10 in total

1.  Can obstructive sleep apnea be a cause of in-stent thrombosis?

Authors:  Anna Hrynkiewicz-Szymanska; Filip M Szymanski; Krzysztof J Filipiak; Marcin Grabowski; Alicja Dąbrowska-Kugacka; Grzegorz Karpinski; Grzegorz Opolski
Journal:  Sleep Breath       Date:  2010-05-23       Impact factor: 2.816

2.  Case records of the Massachusetts General Hospital. Case 30-2012. A 54-year-old woman with HIV infection, dyspnea, and chest pain.

Authors:  Steven G Deeks; Rajesh T Gandhi; Claudia U Chae; Kent B Lewandrowski
Journal:  N Engl J Med       Date:  2012-09-27       Impact factor: 91.245

Review 3.  Cardiovascular implications from untreated human immunodeficiency virus infection.

Authors:  Jason V Baker; Jens D Lundgren
Journal:  Eur Heart J       Date:  2011-01-12       Impact factor: 29.983

4.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Kristian Thygesen; Joseph S Alpert; Harvey D White; Allan S Jaffe; Hugo A Katus; Fred S Apple; Bertil Lindahl; David A Morrow; Bernard A Chaitman; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michael Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis
Journal:  Eur Heart J       Date:  2012-08-24       Impact factor: 29.983

Review 5.  Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis.

Authors:  F M Islam; J Wu; J Jansson; D P Wilson
Journal:  HIV Med       Date:  2012-03-14       Impact factor: 3.180

6.  Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

Authors:  Sylvie Lang; Murielle Mary-Krause; Laurent Cotte; Jacques Gilquin; Marialuisa Partisani; Anne Simon; Franck Boccara; Dominique Costagliola
Journal:  Arch Intern Med       Date:  2010-07-26

7.  Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

Authors:  Roberto Ortiz; Edwin Dejesus; Homayoon Khanlou; Evgeniy Voronin; Jan van Lunzen; Jaime Andrade-Villanueva; Jan Fourie; Sandra De Meyer; Martine De Pauw; Eric Lefebvre; Tony Vangeneugden; Sabrina Spinosa-Guzman
Journal:  AIDS       Date:  2008-07-31       Impact factor: 4.177

8.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

Review 9.  HIV and coronary heart disease: time for a better understanding.

Authors:  Franck Boccara; Sylvie Lang; Catherine Meuleman; Stephane Ederhy; Murielle Mary-Krause; Dominique Costagliola; Jacqueline Capeau; Ariel Cohen
Journal:  J Am Coll Cardiol       Date:  2013-02-05       Impact factor: 24.094

10.  Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.

Authors:  Gilles Montalescot; Stephen D Wiviott; Eugene Braunwald; Sabina A Murphy; C Michael Gibson; Carolyn H McCabe; Elliott M Antman
Journal:  Lancet       Date:  2009-02-28       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.